dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
Published 4 years ago • 276 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:31
dr. kuykendall on toxicity profiles of ruxolitinib and fedratinib in myelofibrosis
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
1:49
dr. kuykendall on the impact of ruxolitinib in myeloproliferative neoplasms
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
7:43
the role of fedratinib in myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:10
fedratinib reemerges as fda-approved treatment of myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
5:10
fedratinib in mf: jakarta2 and freedom trials
-
2:55
novel combinations with ruxolitinib being investigated for myelofibrosis
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors